Co-Administration of Soy Isoflavones and Vitamin D in Management of Irritable Bowel Disease

Jalili, Mahsa; Hekmatdoost, Azita; Vahedi, Homayoon; Khademi, Behnam; Saadi, Mohsen; Zemestani, Maryam; Janani, Leila

doi:10.1371/journal.pone.0158545

Cited by 36 publications

(62 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study by Abbasnezhad et al [23], supplementation with 50,000 IU vitamin D3 biweekly for 6 months in IBS patients reduced GI symptoms of these patients as compared to the control group. Co-administration of soy isoflavones and vitamin D did not improve the IBS-SSS as reported by Jalili et al [25]; however, prescription of vitamin D alone improved clinical symptoms. The exact function of vitamin D in the improvement of clinical symptoms of patients with IBS is unclear.…”

Section: Discussionsupporting

confidence: 64%

Vitamin D3 Supplementation in Diarrhea-Predominant Irritable Bowel Syndrome Patients: The Effects on Symptoms Improvement, Serum Corticotropin-Releasing Hormone, and Interleukin-6 – A Randomized Clinical Trial

et al. 2020

Self Cite

View full text Add to dashboard Cite

Objectives: This study aimed to evaluate whether vitamin D deficiency is associated with the severity of symptoms of irritable bowel syndrome (IBS) patients. Stress and gut inflammation can increase the serum level of corticotropin-releasing hormone (CRH) and interleukin-6 (IL-6), leading to a change in bowel movements. The aim of this study was to evaluate the anti-inflammatory and psychological effects of vitamin D3 supplementation on the symptom improvement of patients with a diarrhea-predominant form of IBS (IBS-D). Methods: Eighty-eight IBS-D patients (age: 18–65 years) based on Rome IV criteria who suffered from vitamin D deficiency and/or insufficiency were enrolled in this randomized, placebo-controlled trial from February 2017 to May 2018 at Rasoul-e-Akram Hospital, Tehran, Iran. Participants were randomly divided into two groups. The intervention group received 50,000 IU vitamin D3 weekly and the control group received a placebo for 9 weeks. All patients received Mebeverine 135 mg twice a day besides supplementation. The IBS Severity Score System (IBS-SSS), serum 25(OH) vitamin D3, CRH, and IL-6 were measured before and after interventions. Results: Seventy-four patients completed the study. The severity of IBS symptoms (p < 0.01) and IL-6 (p = 0.02) decreased significantly in the intervention group as compared to the control group, but there was no significant difference in the serum level of CRH. Also, in the treatment group, IBS-SSS and IL-6 were significantly reduced at the end of the study from baseline (p < 0.01 and p < 0.03, respectively). Conclusion: Our findings indicate that vitamin D3 supplementation can modulate the serum level of CRH and IL-6 and can improve symptoms in IBS-D patients. Vitamin D3 supplementation should be considered in IBS-D patients who suffer from vitamin D deficiency and/or insufficiency.

show abstract

Section: Discussionsupporting

confidence: 64%

Vitamin D3 Supplementation in Diarrhea-Predominant Irritable Bowel Syndrome Patients: The Effects on Symptoms Improvement, Serum Corticotropin-Releasing Hormone, and Interleukin-6 – A Randomized Clinical Trial

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Sample size of 45 IBS patients in each group was required to achieve power of 80% with alpha = 0.05 to detect a difference of 60 in the mean of IBS-SSS (the primary outcome) based on a previous study. [ 22 ] We recruited more than the estimated sample size as we assumed that not all our patients would be compliant with the treatment and hence we increased the sample size in consideration of withdrawal of any patient, which would undermine our results. Moreover, all our patients in group 1 had vitamin D deficiency and were instructed to take therapeutic vitamin D treatment with or without involvement in our study.…”

Section: Methodsmentioning

confidence: 99%

Vitamin D supplementation in adolescents with irritable bowel syndrome: Is it useful? A randomized controlled trial

Amrousy

Hassan

Ashry

et al. 2018

Saudi J Gastroenterol

View full text Add to dashboard Cite

Background/Aim:Vitamin D deficiency is common in irritable bowel syndrome (IBS). There is growing interest in the role of vitamin D in pediatric IBS. We aimed to evaluate the effect of vitamin D supplementation in adolescents with IBS and vitamin D deficiency.Patients and Methods:One hundred and twelve adolescents with IBS and vitamin D deficiency were randomly divided into two groups of matched age and sex. The first group received oral vitamin D3 2000IU/day for 6 months and the second group received placebo for 6 months. Vitamin D status as well as different IBS score systems (IBS-SSS, IBS-QoL, and total score) were evaluated before and 6 months after treatment.Results:IBS patients who received vitamin D supplementation for 6 months showed significant improvement in IBS-SSS (P < 0.001), IBS-QoL (P < 0.001), and total score (P = 0.02) compared to IBS placebo group. IBS patients treated with vitamin D showed two folds increase in their serum vitamin D levels (from 17.2 ± 1.3 to 39 ± 3.3) ng/ml with P < 0.001. While in the placebo group, their serum vitamin D levels were not significantly changed (P = 0.66). Vitamin D was tolerated well without any recorded adverse effects during the study period.Conclusion:Vitamin D supplementation can be effective in treating adolescents with IBS and vitamin D deficiency.

show abstract

“…Evidence of soy isoflavone–reducing effects of GP is new for this research area. It is possible that soy isoflavones would also show benefit in intestinal dysmotility, given the substance has an estrogenic effect on intestinal smooth muscle receptors, aiding cell signaling . From this, diets enriched with soy isoflavones, such as those naturally occurring in soybean products, or fortified foods such as pasta, may also stimulate normal motility and improve digestion in patients with CIPO and SSc.…”

Section: Discussionmentioning

confidence: 99%

“…It is possible that soy isoflavones would also show benefit in intestinal dysmotility, given the substance has an estrogenic effect on intestinal smooth muscle receptors, aiding cell signaling. 33 From this, diets enriched with soy isoflavones, such as those naturally occurring in soybean products, or fortified foods such as pasta, may also stimulate normal motility and improve digestion in patients with CIPO and SSc. There has been speculation that poorly absorbed nutrients such as FODMAPS, especially fructose and lactose, may cause detrimental symptoms in intestinal dysmotility.…”

Section: Discussionmentioning

confidence: 99%

Nutrition Management in Patients With Chronic Gastrointestinal Motility Disorders: A Systematic Literature Review

2019

View full text Add to dashboard Cite

Background The aim of this study was to systematically review effects of nutrition interventions on outcomes in patients with chronic gastrointestinal (GI) motility disorders. There is currently a lack of evidence‐based guidelines for nutrition management in this group, likely a result of the rarity of the conditions. Methods A systematic review of all study types to evaluate current evidence‐based nutrition interventions was performed using Medline, Embase, and CINAHL databases. Two independent reviewers participated in the process of this systematic review. A total of 15 studies and a total of 524 subjects were included. Results Best treatment of this population group was found to include a stepwise process, progressing from oral nutrition to jejunal nutrition and lastly to parenteral nutrition. Small particle, low‐fat diets were significantly better tolerated than the converse, with jejunal nutrition prior to consuming oral food significantly improving oral intake and motility. In more progressive cases, percutaneous endoscopic gastrostomy with jejunal extension nutrition had lower reported symptoms than other enteral routes. Exclusive long‐term parenteral nutrition is a feasible option for advanced cases, with a 68% survival rate at 15 years duration, though oral intake with parenteral nutrition is associated with higher survival rates. Conclusion Treatment of patients with GI motility disorders should first trial oral nutrition. For patients who progress to jejunal or parenteral feeds, the primary aim should be to maintain or reinstate oral intake to reduce morbidity and mortality risk. Higher‐quality studies are still required in this area, particularly in the areas of chronic intestinal pseudo‐obstruction and systemic sclerosis.

show abstract

Co-Administration of Soy Isoflavones and Vitamin D in Management of Irritable Bowel Disease

Cited by 36 publications

References 26 publications

Vitamin D3 Supplementation in Diarrhea-Predominant Irritable Bowel Syndrome Patients: The Effects on Symptoms Improvement, Serum Corticotropin-Releasing Hormone, and Interleukin-6 – A Randomized Clinical Trial

Vitamin D3 Supplementation in Diarrhea-Predominant Irritable Bowel Syndrome Patients: The Effects on Symptoms Improvement, Serum Corticotropin-Releasing Hormone, and Interleukin-6 – A Randomized Clinical Trial

Vitamin D supplementation in adolescents with irritable bowel syndrome: Is it useful? A randomized controlled trial

Nutrition Management in Patients With Chronic Gastrointestinal Motility Disorders: A Systematic Literature Review

Contact Info

Product

Resources

About